The use of botulinum toxin type A in children with cerebral palsy: A retrospective study

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The dosage and safety of botulinum toxin type A (BTX-A) treatments in 104 children with cerebral palsy were examined in a retrospective chart review of a 2-year period at Texas Scottish Rite Hospital for Children. Almost all of the BTX-A injections were to the muscles of the lower limbs. The average dose of BTX-A was 8-9 U/kg body weight and the interval between injections averaged 3-5 months. The average total amount of BTX-A injected at a single visit ranged from 146 to 186 U. The safety record for these treatments was excellent, with only 14 adverse events reported in 257 patient injection visits. The most commonly reported adverse event was muscle weakness, which is related to the pharmacology of BTX-A treatment.

Original languageEnglish (US)
JournalEuropean Journal of Neurology
Volume6
Issue numberSUPPL. 4
StatePublished - 1999

Fingerprint

Type A Botulinum Toxins
Cerebral Palsy
Retrospective Studies
Injections
Safety
Muscle Weakness
Lower Extremity
Therapeutics
Body Weight
Pharmacology
Muscles

Keywords

  • Botulinum toxin type A
  • Cerebral palsy
  • Retrospective analysis
  • Safety

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

@article{6b0d40760eb348a298b51eb19a33e239,
title = "The use of botulinum toxin type A in children with cerebral palsy: A retrospective study",
abstract = "The dosage and safety of botulinum toxin type A (BTX-A) treatments in 104 children with cerebral palsy were examined in a retrospective chart review of a 2-year period at Texas Scottish Rite Hospital for Children. Almost all of the BTX-A injections were to the muscles of the lower limbs. The average dose of BTX-A was 8-9 U/kg body weight and the interval between injections averaged 3-5 months. The average total amount of BTX-A injected at a single visit ranged from 146 to 186 U. The safety record for these treatments was excellent, with only 14 adverse events reported in 257 patient injection visits. The most commonly reported adverse event was muscle weakness, which is related to the pharmacology of BTX-A treatment.",
keywords = "Botulinum toxin type A, Cerebral palsy, Retrospective analysis, Safety",
author = "Delgado, {Mauricio R.}",
year = "1999",
language = "English (US)",
volume = "6",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "SUPPL. 4",

}

TY - JOUR

T1 - The use of botulinum toxin type A in children with cerebral palsy

T2 - A retrospective study

AU - Delgado, Mauricio R.

PY - 1999

Y1 - 1999

N2 - The dosage and safety of botulinum toxin type A (BTX-A) treatments in 104 children with cerebral palsy were examined in a retrospective chart review of a 2-year period at Texas Scottish Rite Hospital for Children. Almost all of the BTX-A injections were to the muscles of the lower limbs. The average dose of BTX-A was 8-9 U/kg body weight and the interval between injections averaged 3-5 months. The average total amount of BTX-A injected at a single visit ranged from 146 to 186 U. The safety record for these treatments was excellent, with only 14 adverse events reported in 257 patient injection visits. The most commonly reported adverse event was muscle weakness, which is related to the pharmacology of BTX-A treatment.

AB - The dosage and safety of botulinum toxin type A (BTX-A) treatments in 104 children with cerebral palsy were examined in a retrospective chart review of a 2-year period at Texas Scottish Rite Hospital for Children. Almost all of the BTX-A injections were to the muscles of the lower limbs. The average dose of BTX-A was 8-9 U/kg body weight and the interval between injections averaged 3-5 months. The average total amount of BTX-A injected at a single visit ranged from 146 to 186 U. The safety record for these treatments was excellent, with only 14 adverse events reported in 257 patient injection visits. The most commonly reported adverse event was muscle weakness, which is related to the pharmacology of BTX-A treatment.

KW - Botulinum toxin type A

KW - Cerebral palsy

KW - Retrospective analysis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0033386127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033386127&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033386127

VL - 6

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - SUPPL. 4

ER -